Trial reportJournal of ultrasound2026
Clinical value of the venous volume excess ultrasound score (VExUS) for volume management following cardiopulmonary bypass (CPB).
Trial report in Journal of ultrasound, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo assess the clinical value of VExUS-guided volume management in patients following CPB surgery.
methodsA single-center, prospective, randomized controlled trial was performed. All adult patients undergoing CPB surgery between January 2024 and October 2025 were consecutively enrolled and randomly allocated in a 1:1 ratio to either a VExUS-guided intervention group or a conventional control group. Baseline demographics, intraoperative surgical parameters, serial postoperative fluid and transfusion metrics, and clinical outcomes were compared between the two cohorts. Intergroup comparisons were conducted using two-tailed statistical tests, with a significance level of P < 0.05.
resultsA total of 89 eligible participants completed the study, including 46 in the VExUS group and 43 in the control group. Baseline clinical profiles and all intraoperative variables showed no statistically significant intergroup differences (all P > 0.05). At 12 h and 24 h postoperatively, the median albumin transfusion volume was 0 g in both groups; however, the VExUS-guided cohort exhibited broader data distribution and a larger proportion of patients receiving high-dose albumin administration, with significant between-group differences (P = 0.007 and P = 0.015, respectively). The median postoperative hospital stay was markedly shorter in the VExUS group (15 days vs. 19 days, P = 0.027). No significant differences were observed in intensive care unit (ICU) or total mechanical ventilation time. Although the cumulative net fluid balance did not reach statistical significance between groups, the VExUS-guided group demonstrated a more prominent negative fluid balance trend at 48 h postoperatively, reflecting greater systemic decongestion.
conclusionVExUS-directed volume management optimizes personalized fluid therapy and shortens postoperative hospital stay in patients undergoing CPB surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.